Prostate cancer patients weigh in: which chemo is easier to tolerate?

NCT ID NCT02044354

Completed Symptom relief Sponsor: Gustave Roussy, Cancer Campus, Grand Paris Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether men with metastatic prostate cancer prefer cabazitaxel or docetaxel as their first chemotherapy. 195 patients tried both drugs in sequence and then stated their preference. The goal is to see if side effects like nerve damage or fatigue influence choice, helping doctors tailor treatment to what matters most to patients.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: cabazitaxel and docetaxel
What this could lead to: If this trial succeeds, it could help doctors choose which chemotherapy patients prefer based on side effects, improving quality of life during treatment.
What could go wrong: This is a completed Phase 3 study, but it only measures patient preference, not survival or cure. Results may not change standard care if one drug is clearly more effective.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma metastatic prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

Contacts and locations

Locations

Gustave Roussy

Villejuif, Val de Marne, 94805, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.